DK1421956T3 - Polyol-IFN-beta-konjugater - Google Patents

Polyol-IFN-beta-konjugater

Info

Publication number
DK1421956T3
DK1421956T3 DK04003053T DK04003053T DK1421956T3 DK 1421956 T3 DK1421956 T3 DK 1421956T3 DK 04003053 T DK04003053 T DK 04003053T DK 04003053 T DK04003053 T DK 04003053T DK 1421956 T3 DK1421956 T3 DK 1421956T3
Authority
DK
Denmark
Prior art keywords
ifn
polyol
beta conjugates
conjugates
beta
Prior art date
Application number
DK04003053T
Other languages
English (en)
Inventor
Tayar Nabil El
Milton Harris
Wayne Sawlivich
Michael J Roberts
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Priority claimed from PCT/US1999/009162 external-priority patent/WO1999055238A1/en
Application granted granted Critical
Publication of DK1421956T3 publication Critical patent/DK1421956T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04003053T 1998-04-28 1999-04-28 Polyol-IFN-beta-konjugater DK1421956T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
PCT/US1999/009162 WO1999055238A1 (en) 1998-04-28 1999-04-28 Anastomotic instrument

Publications (1)

Publication Number Publication Date
DK1421956T3 true DK1421956T3 (da) 2007-10-01

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04003053T DK1421956T3 (da) 1998-04-28 1999-04-28 Polyol-IFN-beta-konjugater
DK99920094T DK1075281T3 (da) 1998-04-28 1999-04-28 Polyol-IFN-beta-konjugater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99920094T DK1075281T3 (da) 1998-04-28 1999-04-28 Polyol-IFN-beta-konjugater

Country Status (31)

Country Link
US (3) US6638500B1 (da)
EP (2) EP1421956B1 (da)
JP (2) JP4574007B2 (da)
KR (1) KR100622796B1 (da)
CN (2) CN1187094C (da)
AR (1) AR020070A1 (da)
AT (2) ATE365563T1 (da)
AU (1) AU762621B2 (da)
BG (2) BG64694B1 (da)
BR (1) BR9910023A (da)
CA (2) CA2330451A1 (da)
CY (1) CY1108022T1 (da)
CZ (2) CZ298579B6 (da)
DE (2) DE69920002T2 (da)
DK (2) DK1421956T3 (da)
EA (2) EA005495B1 (da)
EE (1) EE05214B1 (da)
ES (2) ES2224649T3 (da)
HK (2) HK1038194A1 (da)
HU (1) HUP0300548A3 (da)
IL (1) IL139286A (da)
NO (2) NO329749B1 (da)
NZ (1) NZ507456A (da)
PL (2) PL193352B1 (da)
PT (2) PT1421956E (da)
SI (2) SI1075281T1 (da)
SK (2) SK286654B6 (da)
TR (2) TR200101751T2 (da)
TW (2) TWI232882B (da)
UA (2) UA66857C2 (da)
WO (1) WO1999055377A2 (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
EP2599503B1 (en) * 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
PT1121382E (pt) * 1998-10-16 2006-10-31 Biogen Idec Inc Proteinas de fusao do interferao beta e as respectivas utilizacoes
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
KR100669053B1 (ko) * 1999-04-23 2007-01-15 알자 코포레이션 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
TR200101086A3 (da) * 1999-10-15 2001-08-21
JP4593048B2 (ja) 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
BR0107561A (pt) 2000-01-10 2002-11-19 Maxygen Holdings Ltd Polipeptìdios ou conjugados entre polipeptìdios que exibem atividade (g-csf), métodos de preparação dos mesmos e seus usos
EP1982732A3 (en) 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7291713B2 (en) 2001-01-30 2007-11-06 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
IL156059A0 (en) 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
RS55578B1 (sr) 2002-01-18 2017-06-30 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
BR0317742A (pt) 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de interferon-beta com potência biológica aumentada
ES2327044T3 (es) 2003-03-20 2009-10-23 Bayer Healthcare Llc Variantes de fvii o fviia.
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US8778880B2 (en) * 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
NZ550926A (en) 2004-05-17 2010-01-29 Ares Trading Sa Hydrogel interferon formulations
CN1993139B (zh) 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂
UA93349C2 (ru) 2004-06-01 2011-02-10 Эйрэс Трейдинг C.A. Способ стабилизации мономерного белка интерферона
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
MX2007007471A (es) 2004-12-21 2007-07-20 Nektar Therapeutics Al Corp Reactivos de tiol polimericos estabilizados.
WO2006073846A2 (en) 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
NZ584597A (en) 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
AU2006278490A1 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Conjugates of a G-CSF moiety and a polymer
ES2664924T3 (es) 2005-08-26 2018-04-24 Ares Trading S.A. Procedimiento para la preparación del interferón beta glicosilado
CA2616479A1 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
JP5313129B2 (ja) * 2006-05-02 2013-10-09 アロザイン， インコーポレイテッド 非天然アミノ酸置換ポリペプチド
EP2029738A2 (en) 2006-05-24 2009-03-04 Novo Nordisk Health Care AG Factor ix analogues having prolonged in vivo half life
EA020805B1 (ru) 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
EP2234645B1 (en) * 2007-12-20 2012-05-02 Merck Serono S.A. Peg-interferon-beta formulations
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
WO2009155102A2 (en) * 2008-05-30 2009-12-23 Barofold, Inc. Method for derivatization of proteins using hydrostatic pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
CN102971006A (zh) 2010-07-15 2013-03-13 诺沃—诺迪斯克有限公司 稳定的因子viii变体
EP3466968A1 (en) 2010-09-15 2019-04-10 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP6153470B2 (ja) * 2011-10-01 2017-06-28 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
EP2821079A4 (en) 2012-02-29 2016-05-04 Toray Industries MEANS FOR SUPPRESSING BODY CAVITIES
BR112015024423B1 (pt) 2013-03-29 2023-04-25 Glytech, Inc Polipeptídeo glicosilado tendo atividade de interferon ?, composição farmacêutica e uso de um polipeptídeo glicosilado
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
US11759500B2 (en) 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
LT3183264T (lt) 2014-08-19 2021-01-11 Biogen Ma Inc. Pegilinimo būdas
EP4014985A1 (en) 2015-05-01 2022-06-22 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics for treating ocular disorders
SG10201913935RA (en) * 2015-06-19 2020-03-30 Eisai R&D Man Co Ltd Cys80 conjugated immunoglobulins
EP3612214A4 (en) * 2017-04-17 2021-01-20 The Regents of the University of Colorado, A Body Corporate OPTIMIZATION OF ALTERNATIVE ENZYMOTHERAPY FOR THE TREATMENT OF HOMOCYSTINURIA
CA3124682A1 (en) 2019-01-28 2020-08-06 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
EP3964266A4 (en) 2019-01-28 2022-12-28 Toray Industries, Inc. POLYETHYLENE GLYCOL MODIFIED FORM OF HEPATOCYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0730470B1 (en) 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
HU218893B (hu) * 1994-03-31 2000-12-28 Amgen Inc. A megakariocita szaporodás és differenciálódás stimulálására szolgáló módszerek és vízoldható készítmények
WO1995031479A1 (en) * 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
ATE200030T1 (de) * 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
SK16222000A3 (sk) 2001-04-09
NO20100324L (no) 2000-12-28
BG65046B1 (bg) 2007-01-31
TWI266800B (en) 2006-11-21
NO20005337L (no) 2000-12-28
DE69920002T2 (de) 2005-09-22
US7357925B2 (en) 2008-04-15
BG104871A (en) 2001-07-31
WO1999055377A2 (en) 1999-11-04
CN100335503C (zh) 2007-09-05
CZ20003995A3 (en) 2001-06-13
WO1999055377A3 (en) 1999-12-29
ES2224649T3 (es) 2005-03-01
UA66857C2 (uk) 2004-06-15
HUP0300548A2 (hu) 2003-06-28
TR200003161T2 (tr) 2001-01-22
DK1075281T3 (da) 2005-01-03
BG109291A (en) 2006-04-28
EA200300382A1 (ru) 2005-02-24
CA2330451A1 (en) 1999-11-04
WO1999055377A9 (en) 2000-03-02
PL196533B1 (pl) 2008-01-31
AU3767499A (en) 1999-11-16
UA79430C2 (en) 2007-06-25
KR100622796B1 (ko) 2006-09-13
EA003789B1 (ru) 2003-10-30
EP1421956A1 (en) 2004-05-26
ATE275422T1 (de) 2004-09-15
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
NO332224B1 (no) 2012-07-30
SK286217B6 (sk) 2008-05-06
EE200000614A (et) 2002-04-15
SK286654B6 (sk) 2009-03-05
CN1187094C (zh) 2005-02-02
JP4574007B2 (ja) 2010-11-04
DE69936409D1 (de) 2007-08-09
TWI232882B (en) 2005-05-21
DE69936409T2 (de) 2008-04-17
CZ298579B6 (cs) 2007-11-14
PT1421956E (pt) 2007-07-13
PL344490A1 (en) 2001-11-05
EP1075281A2 (en) 2001-02-14
IL139286A0 (en) 2001-11-25
EP1421956B1 (en) 2007-06-27
JP2002512983A (ja) 2002-05-08
HK1038194A1 (en) 2002-03-08
US7700314B2 (en) 2010-04-20
US6638500B1 (en) 2003-10-28
SI1421956T1 (sl) 2007-10-31
AR020070A1 (es) 2002-04-10
NZ507456A (en) 2003-10-31
BG64694B1 (bg) 2005-12-30
CN1637020A (zh) 2005-07-13
PT1075281E (pt) 2004-11-30
CZ298597B6 (cs) 2007-11-21
US20070141620A1 (en) 2007-06-21
PL193352B1 (pl) 2007-02-28
AU762621B2 (en) 2003-07-03
ATE365563T1 (de) 2007-07-15
CA2565375A1 (en) 1999-11-04
DE69920002D1 (de) 2004-10-14
IL139286A (en) 2005-12-18
BR9910023A (pt) 2000-12-26
TR200101751T2 (tr) 2002-05-21
NO329749B1 (no) 2010-12-13
KR20010071158A (ko) 2001-07-28
EA005495B1 (ru) 2005-02-24
SI1075281T1 (en) 2005-02-28
EA200001111A1 (ru) 2001-04-23
CN1302209A (zh) 2001-07-04
HUP0300548A3 (en) 2005-07-28
HK1076115A1 (en) 2006-01-06
US20040043002A1 (en) 2004-03-04
JP2010184929A (ja) 2010-08-26
ES2285286T3 (es) 2007-11-16
NO20005337D0 (no) 2000-10-23
CY1108022T1 (el) 2013-09-04

Similar Documents

Publication Publication Date Title
DK1075281T3 (da) Polyol-IFN-beta-konjugater
DE59914158D1 (de) Metallocenmonohalogenide
ATE341990T1 (de) Sigmidoskop
NO20012596L (no) Rörforankring
DE59911453D1 (de) Aktivkohlefilter
DE69808145D1 (de) Tintenbehälternachfüllsystem
DE69904565T2 (de) Hubventilsteuerungseinrichtung
DE59901560D1 (de) Retrograder tibianagel
DE59912371D1 (de) Gleitschalungsfertiger
DE69921320D1 (de) Turbinenstatorschaufel
DE59907306D1 (de) Fadenchangierung
DE59906931D1 (de) Exzenterzahnradgetriebe
DE59911683D1 (de) Fahrzeugschliessanlage
DE59908968D1 (de) Benzoylpyridazine
DE59913393D1 (de) Fadenchangierung
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59908057D1 (de) Underdruckhandhabungseinrichung
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59807217D1 (de) Nadellager
DE1118098T1 (de) Mehrfachflussigelektrosprühschnittstelle
DE59808995D1 (de) Endomikroskopsystem
DE19842103B4 (de) Stanznietzuführung
DE59902088D1 (de) Achrathermer Reimager
DE59900612D1 (de) Dispersionsazofarbstoffmischungen